Pular para o conteúdo
Menu
Mix Vale

Japan approves 20-valent pneumococcal vaccine for routine vaccination of elderly people from 2026

Beatriz
Por 2 min de leitura
Compartilhe
Vacina pneumocócica
Foto: Vacina pneumocócica - chemical industry/shutterstock.com

The Ministério of Saúde, Trabalho and Bem-Estar of

Publicidade

The measure comes into force from April 2026 and replaces the 23-valent polysaccharide vaccine (PPSV23), previously used.

The subcommittee on basic vaccination policies considered aspects such as effectiveness, safety and cost-effectiveness of PCV20.

Publicidade

The target population includes people aged 65 and over.

  • It includes individuals aged 60 to 64 with severe dysfunction in organs such as the heart, kidneys or lungs.
  • It also includes those with severe immunological compromise due to HIV.

Details of the transition to PCV20

The change comes after evaluations that indicate greater protection of PCV20 against circulating serotypes.

Studies show that the conjugate vaccine maintains longer-lasting immune responses compared to the previous one.

The committee decided not to implement transitional measures for people over 65 years of age already vaccinated with PPSV23.

Vacina
Vaccine – Foto: Jay_Zynism/istock

Target audience and inclusion criteria

People over the age of 65 receive the vaccine in a single dose as part of the regular program.

Publicidade

Individuals between the ages of 60 and 64 qualify only with specific conditions that limit daily activities.

  • Severe cardiac, renal or respiratory dysfunction.
  • Immune compromise due to HIV that makes routine life almost impossible.

Excluding transitions avoids administrative burden on local governments.

Reasons for not adopting transitional measures

The committee highlighted existing opportunities for PPSV23 vaccination.

The effectiveness of this vaccine decreases with advancing age.

Adding transitions would increase the burden on municipalities responsible for implementation.

Experts reinforce that PCV20 offers broader coverage against invasive pneumococcal infections.

Benefits of the new conjugate vaccine

PCV20 protects against 20 serotypes of the bacteria Streptococcus pneumoniae.

These serotypes account for a significant portion of pneumonia and meningitis in the elderly.

The conjugate technology improves the immune response in elderly populations.

Approval data indicates a similar safety profile to previous vaccines.

Implementation from 2026

Vaccination begins in April, in line with the Japanese fiscal calendar.

Municipalities organize distribution and application at health centers.

Replacement of PPSV23 occurs gradually with existing stock.

Health professionals advise patients on updating the program.

Public health context in Japão

The country is facing accelerated population aging, with a high proportion of elderly people.

Respiratory infections represent a high risk in this age group.

Immunization programs seek to reduce hospitalizations for preventable diseases.

The inclusion reflects advances in higher valence pneumococcal vaccines.

Notícias relacionadas